The S&P/ASX 200 Heathcare Index closed in the black on Friday for the third week in a row, as the wider market slipped for the second week in a row.
Like a spent fighter coming back from the brink after teetering on the ropes in the dying stages, the federal government’s R&D Tax Credit bill is still standing at the 12th round bell with only one more round to go.
Australian scientists today paid tribute to the distinguished life and career of Professor Frank Fenner AC, MBE who passed away today aged 95.
Twelve months after the release of the initial draft of the R&D Tax Credit, a series of false starts, contested claims and last minute legislative changes have seen the proposed 1 July 2010 start date come and go, with no resolution to the confusion in sight.
The S&P/ASX 200 Heathcare Index managed to sneak into positive territory this week, adding to last week’s strong gains.
Troubled HIV treatment developer Avexa will pay around $1.5 million to acquire up to 24 percent of Western Australia medical devices company Allied Medical under the terms of a deal revealed this week.
The R&D Tax Credit legislation has had a chequered past, going through multiple revisions and stalling before entering the Senate prior to the federal election.
The federal government has named the 21-strong expert advisory panel who will help chart the direction of its $38.2 million National Enabling Technologies Strategy.
The federal government today announced the formation of four new funds with a combined war chest of $160 million to support Australian innovation.
The governments of Australia and China have announced that they will jointly fund a new state-of-the-art nanotechnology laboratory in China.
Federal innovation Minister Senator Kim Carr today announced the opening of round 14 of the CRC ( cooperative research centres) program, inviting companies around Australia to partner up and submit their applications for funding.
PricewaterhouseCoopers has released its Q1FY11 BioForum report on Australia’s life sciences and biotech equities, revealing that the sector went backwards slightly as the wider market advanced.
Melbourne biotech Hatchtech announced today that it has raised $6.3 million to fund Phase IIb clinical trials for its novel treatment for head lice.
The heavy back-slapping and self-congratulations at this week’s AusBiotech 2010 shindig in Melbourne may have rubbed off a little on the S&P/ASX 200 Healthcare Index, which managed to claw back most of last week’s losses.
Any doubts as to the marketability of the Australian biotech and life sciences industries were thoroughly dispelled this week with 150 investors from more than 100 companies - foreign and Australian - attending AusBiotech’s Australasian Life Sciences Investment Summit in Melbourne as part of AusBiotech 2010.